Mineralys Therapeutics Issues Corporate Update on Clinical Progress
Mineralys Therapeutics issued a corporate update highlighting several recent and upcoming clinical and regulatory milestones. Recent Clinical Highlights and Upcoming Milestones: Explore-OSA Phase 2 Trial; Lorundrostat New Drug Application; Transform-HTN Open-Label Extension Trial; Explore-CKD Phase 2 Trial; Launch-HTN Phase 3 Trial; Advance-HTN Trial
